

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS, LLC and  
PAR PHARMACEUTICAL, INC  
Petitioners

v.

JAZZ PHARMACEUTICALS, INC.  
Patent Owner

---

CASE IPR2015-00554  
Patent 7,668,730

---

**PETITIONERS' REPLY REGARDING THE IDENTIFICATION OF REAL  
PARTIES IN INTEREST**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TABLE OF CONTENTS**

I. INTRODUCTION ..... 1

II. LEGAL STANDARD ..... 1

III. FACTUAL BACKGROUND..... 2

IV. THE PETITIONS CORRECTLY IDENTIFY PAR INC. AS THE REAL PARTY IN INTEREST..... 3

    A. None of the Par Parents Have a Tangible Interest in the Petitions.....4

    B. Par Inc. Has Exercised Sole Direction and Control Over the Petitions.....5

        1. The Board Has Found the Type of Evidence Jazz Presents Here Insufficient to Confer RPI Status on a Non-Party..... 5

        2. Prior Board Decisions Finding Non-Party Parent Companies To Be RPIs Are Distinct From the Present Case..... 8

V. CONCLUSION..... 10

## **I. INTRODUCTION**

Pursuant to the Board’s Order on May 12, 2015 (Paper 11), Petitioner Par Pharmaceutical, Inc. (“Par Inc.”) hereby responds to Jazz Pharmaceuticals, Inc.’s (“Jazz”) assertion that the above-captioned petition for *inter partes* review failed to name Par Inc.’s direct and indirect parent holding companies as “real parties-in-interest” (“RPI”). The Board should reject Jazz’s arguments as they fail to establish that Par Inc.’s parent holding companies have an interest in or control over this proceeding sufficient to render them RPIs.

## **II. LEGAL STANDARD**

The patent owner challenging a Petitioner’s RPI disclosure must provide sufficient evidence to show the disclosure is inadequate. *Intellectual Ventures Mgmt, LLC v. Xilinx, Inc.*, IPR2012-00018, Paper 12 at 3 (P.T.A.B. Jan. 24, 2013). The RPI is “the party that desires review of the patent”—that is, the party “at whose behest the petition has been filed.” Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,759 (Aug. 14, 2012) (to be codified at 37 C.F.R. Pt. 42). The RPI requirement exists to ensure that a non-party is not “litigating through a proxy.” *See Aruze Gaming Macau, Ltd. v. MGT Gaming, Inc.*, IPR2014-01288, Paper 13, at 12 (P.T.A.B. Feb. 20, 2015). Moreover, the RPI analysis is a narrowly tailored inquiry into the “relationship between a party and a *proceeding*,” not “the relationship between *parties*.” *Id.* at 11.

The mere existence of a parent-subsidary relationship “does not establish a relationship sufficient to make the parent a real party in interest.” *TRW Automotive U.S. LLC v. Magna Elec. Inc.*, IPR2014-01499, Paper 7 at 11 (P.T.A.B. Mar. 19, 2015). Instead, Patent Owner must sufficiently demonstrate with evidence that the parent controls a subsidiary’s participation in the *inter partes* review. *Compass Bank v. Intellectual Ventures II*, IPR2014-00719, Paper 11 at 8 (P.T.A.B. Oct. 24, 2014).

### **III. FACTUAL BACKGROUND**

Par Inc. is the wholly-owned subsidiary of a series of holding companies, including Par Pharmaceutical Companies, Inc. (“Par Co.”); Sky Growth Intermediate Holdings II, Inc. (“SGIH II”); Sky Growth Intermediate Holdings I, Inc. (“SGIH I”); and Par Pharmaceutical Holdings, Inc. (“Par Holdings”) (collectively, the “Par Parents”). (PAR1040, ¶2.) Par Inc. is engaged in the business of making, selling and distributing pharmaceuticals; the Par Parents, however, do not conduct any such operations. (*Id.*, ¶¶ 2–4.)

Par Inc. prepared and filed ANDA No. 205403 (“Par’s ANDA”) with the United States Food and Drug Administration, directed to a 500 mg/ml solution of sodium oxybate (“Par’s ANDA Product”), and holds all right and title to that ANDA (*Id.*, ¶5.) Par’s ANDA includes “Paragraph IV” certifications that U.S. Patent Nos. 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,457,988; and 8,589,182

(collectively, “the Petition Patents”) are invalid or would not be infringed by Par’s ANDA Product. Based on that ANDA filing, Jazz sued Par Inc.—and, after nearly eighteen months of litigation, has yet to sue any of the Par Parents—for infringement of the Petition Patents, among others, and seeking a declaration that Par’s ANDA Product would infringe them upon FDA approval. (*See* PAR1026 at 16–23.)

**IV. THE PETITIONS CORRECTLY IDENTIFY PAR INC. AS THE REAL PARTY IN INTEREST.**

Far from being a “nominal plaintiff” with “no substantial interest,” Par Inc. is the *only* Par entity with a cognizable interest in these Petitions, and is the only Par entity that has maintained any control over their preparation and filing.<sup>1</sup> Jazz has failed to offer credible evidence that Par Inc. is acting as a proxy for the Par Parents, or that the Par Parents control these Petitions so as to render them RPIs.<sup>2</sup>

---

<sup>1</sup> Amneal Pharmaceuticals LLC, of course, is also an RPI with respect to IPR2015-00545, -00546, -00547, and -00554.

<sup>2</sup> Notably, Jazz named Jazz Pharmaceuticals, Inc. as the sole RPI in its Mandatory Notices, (*see* Paper 8 at 2) despite Jazz being a wholly-owned subsidiary of Jazz Pharmaceuticals PLC, which could presumably control or direct its behavior in these proceedings as well for the same reasons. (*See* PAR1041 at 29

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.